Abstract: The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of long chain fatty acid to the colon by bypassing the upper digestive tract.
Abstract: Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines. The present invention refers to pharmaceutically acceptable compounds of Formula I, their salts and derivatives, where (a) and (b) can take any value between 0 and 14, (X) can be substituted by any atom or group of atoms with an atomic/molecular weight between 4 and 200 Da and (R) can be substituted by any atom or group of atoms with an atomic/molecular weight between 1 and 200 Da, for use as medicines.
Type:
Grant
Filed:
December 4, 2009
Date of Patent:
April 7, 2015
Assignee:
Universitat de les Illes Balears
Inventors:
Pablo Vicente Escribá Ruiz, Xavier Busquets Xaubet, Gwendolyn Barceló Coblijn, Victoria Lladó Cañellas, Rafael Álvarez Martínez, Silvia Teres Jiménez, Daniel López, Juana Barceló Estarellas, Julian Taylor Green, Gerardo Ávila Martín
Abstract: An aqueous disinfecting solution having a pH of from about 0.5 to about 6 consists essentially of hydrogen peroxide in a concentration of from about 0.05 to about 8 w/w % of the total solution, at least one anionic surfactant in a concentration of from about 0.02 to about 8 w/w % of the total solution, and at least one additional ingredient chosen from benzyl alcohol, an alcohol comprising one to six carbon atoms, and mixtures thereof, in a concentration of from about 0.1 to about 10 w/w % of the total solution.
Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, and/or 15-HETrE, used singly or in combination for the prevention and/or treatment of effects associated with UV radiation such as erythema.
Type:
Application
Filed:
December 9, 2014
Publication date:
April 2, 2015
Inventors:
Mehar Manku, John Climax, David Coughlan
Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, 15-OHEPA and/or 15-HETrE, used singly or in combination with anti-bacterial agents for the inhibition of sebum production.
Type:
Application
Filed:
December 11, 2014
Publication date:
April 2, 2015
Inventors:
Mehar Manku, David Coughlan, Bill Downes, John Climax
Abstract: Activated fatty acids, topical compositions including activated fatty acids and methods for using activated fatty acids to treat a variety of diseases.
Abstract: Activated fatty acids, nutraceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.
Abstract: The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide.
Type:
Application
Filed:
September 29, 2014
Publication date:
March 26, 2015
Applicant:
YALE UNIVERSITY
Inventors:
Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
Abstract: A composition which is adapted for oral consumption and which is in the form of a substantially homogeneous aqueous emulsion, suspension or dispersion comprising salicylic acid, or a C1 to C6 alkyl ester thereof, and docosahexaenoic acid (DHA) can exhibit an anti-inflammatory effect in skin.
Type:
Grant
Filed:
April 5, 2007
Date of Patent:
March 24, 2015
Assignee:
Conopco, Inc.
Inventors:
John Casey, Alexander Gordon James, Gail Jenkins, Linda Jane Wainwright
Abstract: The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DHA, EPA and/or GLA, used in combination with one or more antibiotic agents for the treatment of disease and/or disorders such as a skin or ocular infection.
Type:
Application
Filed:
September 19, 2014
Publication date:
March 19, 2015
Inventors:
Mehar Manku, John Climax, Jonathan Rowe
Abstract: The subject invention thus provides a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said at least one phospholipid and uses thereof.
Type:
Grant
Filed:
November 2, 2008
Date of Patent:
March 10, 2015
Assignee:
Enzymotec Ltd.
Inventors:
Fabiana Bar Yosef, Dori Pollod, Ariel Katz
Abstract: The subject invention relates to a variety of formulations of bipolar trans carotenoids including pharmaceutical compositions for oral delivery of a bipolar trans carotenoid comprising i) a bipolar trans carotenoid, ii) a cyclodextrin, and iii) a coating. The invention also relates to preparation of such formulations and their uses.
Abstract: Methods of producing an unsaturated free fatty acid comprising at least 18 carbon atoms are provided. In some embodiments, the methods comprise culturing an engineered microorganism in a culture medium, wherein the engineered microorganism comprises at least one recombinant enzyme selected from acyl-lipid desaturase delta-9 (EC:1.14.19.1), acyl-lipid desaturase delta-12 (EC:1.14.19.6), acyl-lipid desaturase delta-15 (EC:1.14.19.-), and thioesterase (EC:3.1.2.14). Engineered microorganisms comprising at least one of those recombinant enzymes are also provided. The methods and organisms can be used to produce at least one free fatty acid selected from oleic acid, linoleic acid and ?-linolenic acid.
Type:
Application
Filed:
July 18, 2014
Publication date:
February 26, 2015
Inventors:
Subhayu Basu, Gaozhong Shen, Brett Adam Boghigian, David M. Young, David Arthur Berry, Geoffrey von Maltzahn
Abstract: Eicosapentaenoic acid (EPA) compositions and EPA-rich polar lipids for prophylactic or therapeutic applications are described. Production from certain cultured micro-organisms (like Nitzschia laevis) promotes synthesis of EPA, including polar lipids including EPA. The EPA-rich polar lipids themselves may be used as polar compounds. EPA can be selectively hydrolyzed from particular positions in isolated polar lipids by lipase activity, then optionally further purified. The process bypasses reliance on diminishing fish stocks and on physico-chemical processes that may not adequately separate desirable n-3 HUFAs from unwanted products like DHA also found in fish oil and cultured organisms.
Type:
Application
Filed:
November 3, 2014
Publication date:
February 26, 2015
Inventors:
Karl Thomas GEIRINGER, Hywel David Griffiths
Abstract: It is intended to provide a composition having at least one effect among the following effects; a plurality of medicinal ingredients can be taken as one preparation and the convenience for patients is excellent; the drug compliance is excellent; the amount of jelly composition to be taken at a time is small; the release of an active ingredient in the digestive tract is excellent; the absorption of an active ingredient to the body is excellent; the storage stability of an active ingredient is excellent; the dispersibility of an active ingredient in the composition is excellent; the storage stability of the composition is excellent; the syneresis of the composition is less, it has an appropriate jelly strength to a degree that does not disintegrate during carrying and before taking and easily disintegrates after taking; the handleability during preparation of the composition is excellent; the portability of the composition is excellent; the feeling of taking the composition is excellent; it has an effect on red
Abstract: A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals.
Type:
Application
Filed:
October 27, 2014
Publication date:
February 19, 2015
Inventors:
Banavara L. Mylari, Frank C. Sciavolino
Abstract: PknG from Mycobacterium tuberculosis is a Ser/Thr protein kinase that regulates key metabolic processes within the bacterial cell as well as signaling pathways from the infected host cell. This multi-domain protein has a conserved canonical kinase domain with N- and C-terminal flanking regions of unclear functional roles. The N-terminus harbors a rubredoxin-like domain (Rbx), a bacterial protein module characterized by an iron ion coordinated by four cysteine residues. Disruption of Rbx-metal binding site by simultaneous mutations of all the key cysteine residues significantly impairs PknG activity. This encouraged us to evaluate the effect of a nitro-fatty acid (9- and 10-nitro-octadeca-9-cis-enoic acid; OA-NO2) on PknG activity. Fatty acid nitroalkenes are electrophilic species produced during inflammation and metabolism that react with nucleophilic residues of target proteins (i.e. Cys and His), modulating protein functions and subcellular distribution in a reversible-manner.
Type:
Application
Filed:
June 16, 2014
Publication date:
February 19, 2015
Inventors:
Carlos Ignacio Batthyany Dighiero, Rosario Duran
Abstract: The invention concerns topical compositions for the prevention and treatment of ocular pathologies, in particular inflammatory keratites and conjunctivites and dry eye syndrome, containing as active ingredients polyunsaturated fatty acids of the types omega-3 and omega-6, and specifically EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid) and GLA (?-linolenic acid), mixed with vitamin E acetate and formulated in a stable composition in hydrogel, i.e. in dispersed form in an aqueous vehicle containing one or more gelling polymers. The proposed compositions are particularly indicated for use as artificial tears.
Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenerative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
Abstract: Methods and compositions are provided for inducing physiologic hypertrophy in a cell for treatment or prevention of a cardiovascular disease or condition.
Type:
Application
Filed:
February 27, 2014
Publication date:
February 12, 2015
Inventors:
Leslie A. Leinwand, Cecilia Riquelme, Brooke Harrison, Jason Magida
Abstract: The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
Type:
Grant
Filed:
August 13, 2012
Date of Patent:
February 10, 2015
Assignee:
Pivotal Therapeutics Inc.
Inventors:
George Jackowski, Rachelle MacSweeney, Nisar Shaikh, Jason Yantha, Valerie Schini-Kerth
Abstract: An orodispersible composition without bad odor, smell, or taste comprising polyunsaturated fatty acids (PUFA) and a disintegrant. The disintegrant is a solid dispersion comprising mannitol, xylitol, microcrystalline cellulose, crospovidone and dibasic calcium phosphate. A process of preparing the composition and its use as nutritional or dietary supplement for balancing the blood lipid level, preventing or reducing the risk of the development of atherosclerotic changes, disorders or diseases.
Abstract: The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.
Type:
Grant
Filed:
May 3, 2006
Date of Patent:
February 3, 2015
Assignee:
Warsaw Orthopedic, Inc.
Inventors:
Josee Roy, William F. McKay, Jeffrey C. Marx
Abstract: Disclosed is a PLGA (poly(D,L-lactide-co-glycolide)) cell scaffold. The cell scaffold is based on a PLGA scaffold, which is an FDA-approved material with no cytotoxicity, and overcomes the problem with conventional PLGA scaffolds of poor cell adhesion.
Type:
Application
Filed:
May 9, 2014
Publication date:
January 29, 2015
Applicant:
DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY
Abstract: Provided are compounds and compositions derived from Pseudomonas sp., particularly, Pseudomonas fluorescens or Pseudomonas protegens and more particularly strain having the identifying characteristics of Pseudomonas ATCC 55799 having antimicrobial properties and particularly, antibacterial properties.
Type:
Application
Filed:
February 27, 2013
Publication date:
January 29, 2015
Applicant:
Marrone Bio Innovations, Inc.
Inventors:
Ratnakar Asolkar, Ana Lucia Cordova-Kreylos, Carly Todd
Abstract: The present invention relates to the treatment and/or prevention of Alzheimer's Disease or the symptoms associated therewith by daily administration of a drink formula comprising fresh marine omega-3 oil in an emulsion and resveratrol or derivatives thereof.
Abstract: The application relates to an encapsulated composition comprising from about 40% (w/w) to about 90% (w/w) of the encapsulating composition comprising from about 14% (w/w) to about 90% (w/w) whey protein isolate with a special ionic profile, from about 5% (w/w) to about 80% (w/w) of one or more low molecular weight carbohydrates, and from about 3% (w/w) to about 15% (w/w) antioxidant; and encapsulating from about 10% (w/w) to about 60% (w/w) polyunsaturated fatty acids.
Type:
Application
Filed:
July 29, 2013
Publication date:
January 29, 2015
Applicant:
Corn Products Development, Inc.
Inventors:
Amir Malaki Nik, Jason Zhixin Li, Joseph M. Light, Mei Yin Wang
Abstract: The present disclosure is directed to methods for enhancing, improving or increasing fertility or reproductive function. For example, the present disclosure is directed to a method for enhancing, improving, or increasing a female human's likelihood of becoming pregnant comprising: administering to the human a nutritional, dietary, or food fatty acid supplement comprising: at least 30% docosahexaenoic acid (DHA), by weight of the total fatty acids in the supplement in a form chosen from ethyl ester, free fatty acid, and triglyceride.
Abstract: Activated fatty acids, topical compositions including activated fatty acids and methods for using activated fatty acids to treat a variety of diseases.
Abstract: A class of enzymatically generated electrophilic fatty acid derivatives (EFADs), or their enzymatically generated metabolites. The EFAD's and their metabolites have beneficial effects human health. According to the inventors the inventive keto fatty acids or their enzymatically generated metabolites, can inhibit inflammation by giving rise to adaptive signaling molecules in vivo.
Type:
Application
Filed:
February 1, 2013
Publication date:
January 15, 2015
Inventors:
Bruce A. Freeman, Francisco J. Schopfer
Abstract: The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis.
Type:
Application
Filed:
July 25, 2014
Publication date:
January 15, 2015
Inventors:
Klaske VAN NORREN, Joyce FABER, Adrianus Lambertus Bertholdus VAN HELVOORT, Robert Johan Joseph HAGEMAN
Abstract: Mixture of fatty acids, their derivatives, ester or methyl ester derivates thereof, which may be administered to non-human mammals by diffusion in to ambient air during at least seven consecutive days, with a rapid kinetic of diffusion during the first three days of administration.
Abstract: The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ALS, by administering these compounds or pharmaceutical compositions to subjects in need thereof.
Abstract: The present invention provides methods of identifying a subject as responsive to treatment of an inflammatory disease and/or inflammation with one or more polyunsaturated fatty acids (PUFAs), comprising detecting, in a nucleic acid sample of a subject having an inflammatory disease and/or inflammation, the presence of a C allele at single nucleotide polymorphism (SNP) rs730012 in the leukotriene C4 synthase gene, wherein the presence of said C allele at rs730012 in said nucleic acid sample from the subject indicates that the subject is responsive to treatment of said inflammatory disease and/or inflammation with one or more PUFAs.
Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented. Also provided are methods of treating hypertriglyceridemia (200 mg/dL-500 mg/dL) by adjunctive administration of a statin and the pharmaceutical compositions described herein. Further treatment methods include, inter alia, treatments to increase plasma EPA:AA ratios, treatments to decrease ApoCIII levels, and treatments to reduce or prevent resistance to platelet aggregation inhibitors.
Type:
Application
Filed:
January 4, 2013
Publication date:
January 1, 2015
Inventors:
Timothy J. Maines, Bernardus Machielse, Bharat M. Mehta, Gerald Wisler, Michael Davidson, Peter Ralph Wood
Abstract: Processes for enhancing ability to learn in a puppy or kitten comprising orally administering to the puppy or kitten a composition comprising an essential fatty acid component comprising a therapeutically effective amount of docosahexaenoic acid. Processes for enhancing ability to learn in a puppy or kitten comprising orally administering to a respective maternal animal a composition comprising an essential fatty acid component comprising a therapeutically effective amount of docosahexaenoic acid during gestation, nursing, or weaning of the puppy or kitten. Kits comprising a composition comprising an essential fatty acid component comprising a therapeutically effective amount of docosahexaenoic acid; and information that use of the composition will enhance ability to learn in a puppy or kitten.
Abstract: The present disclosure provides nutritional compositions comprising docosahexaenoic acid (DHA) and arachidonic acid (ARA). The nutritional compositions may comprise an emulsion of docosahexaenoic acid (DHA) and arachidonic acid (ARA), and are suitable for enteral delivery as a nutritional supplement or for oral delivery as a human milk or infant formula fortifier. Additionally, the present disclosure provides methods for delivering nutrients to subjects requiring small-volume nutritional support, such as preterm infants. The nutritional compositions are useful, for example, in correcting nutritional deficiencies by increasing a subject's intake of nutrients, such as ?-3 or ?-6 long-chain polyunsaturated acids.
Type:
Application
Filed:
June 21, 2013
Publication date:
December 25, 2014
Inventors:
John Alvey, Carol Berseth, Deborah Schade
Abstract: The present invention comprises a method of improving bone health and muscle health in a companion animal comprising administering a composition comprising a fatty acid component to the companion animal wherein the fatty acid component comprises a ratio of docosahexaenoic acid (DHA) to eicosapentaenoic acid (EPA) from about 3:1 to about 25:1. The present invention additionally comprises a composition comprising a fatty acid component comprising docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) wherein the ratio of docosahexaenoic acid (DHA) to eicosapentaenoic acid (EPA) is from about 3:1 to about 25:1.
Type:
Application
Filed:
September 8, 2014
Publication date:
December 25, 2014
Inventors:
Bruce Alan Watkins, Kevin Mark Hannon, Allan John Lepine
Abstract: A composition and method for supplementing food, nutrition, and diet systems with omega-6 to omega-3 balanced oils comprising a synergistic blend of at least two oils. The composition further comprises a synergistic blend of long chain omega-3 oil as a means to further increase the nutritional value. The composition provides an effective increase in therapeutic and pharmacological properties in nutrition and diet systems.
Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
Abstract: The present invention provides a compound of Formula (I), wherein: each X is independently hydrogen or deuterium; and at least one X is deuterium.
Abstract: Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.
Type:
Application
Filed:
July 26, 2012
Publication date:
December 11, 2014
Applicant:
Allergan Inc.
Inventors:
Anuradha V. Gore, Sai Shankar, Sukhon Likitiersuang, Chetan P. Pujara, Sesha Neervanna
Abstract: A method for influencing behavior in young, adult or aged pet animals which comprises systemically administering a behavior influencing quantity of an omega-3 fatty acid or mixture of omega-3 fatty acids.
Type:
Application
Filed:
August 15, 2014
Publication date:
December 4, 2014
Inventors:
Steven Curtis Zicker, Chadwick E. Dodd, Dennis Jewell, Dale A. Fritsch
Abstract: Compositions and methods for treating infectious diseases produced by biofilms are disclosed. More specifically, the present disclosure refers to a pharmaceutical compositions which may be used for treating biofilm infections, specifically, biofilms formed by bacteria such as Pseudomonas, E. coli, Klebsiella, and other human pathogens. Pharmaceutical compositions may include a nutrient dispersion that can include sodium citrate, succinic acid, xylitol, glutamic acid, and ethylenediaminetetraacetic acid (EDTA), among others. Additionally disclosed pharmaceutical composition may include API such as antibiotics. Subsequently, the antibiotics agent may be ciprofloxacin, amikacin, tobramycin, colistin methate, or polymixin, among others. Pharmaceutical compositions disclosed may employ chemotactic agents in order to disrupt biofilms and therefore enhance the antibiotic response. Pharmaceutical compositions disclosed may include suitable vehicles which may depend on the dosage form.
Type:
Application
Filed:
May 22, 2013
Publication date:
November 27, 2014
Applicant:
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Abstract: The present invention comprises a method of improving bone health and muscle health in a companion animal comprising administering a composition comprising a fatty acid component to the companion animal wherein the fatty acid component comprises a ratio of docosahexaenoic acid (DHA) to eicosapentaenoic acid (EPA) from about 3:1 to about 25:1. The present invention additionally comprises a composition comprising a fatty acid component comprising docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) wherein the ratio of docosahexaenoic acid (DHA) to eicosapentaenoic acid (EPA) is from about 3:1 to about 25:1.
Type:
Application
Filed:
July 30, 2014
Publication date:
November 20, 2014
Inventors:
Allan John Lepine, Bruce Alan Watkins, Kevin Mark Hannon
Abstract: The present invention provides for a novel lipokine, trans-C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, low concentrations of trans-C16:1n7-palmitoleate the serum indicates a risk of metabolic disease. Additionally, administering trans C16:1n7-palmitoleate to a subject (via pharmaceutical, nutraceutical, or other means), positively impacts glucose metabolism.
Type:
Grant
Filed:
July 11, 2011
Date of Patent:
November 18, 2014
Assignee:
President and Fellows of Harvard College
Inventors:
Dariush Mozaffarian, Haiming Cao, Gokhan S. Hotamisligil
Abstract: The present invention relates to compositions having an antifungal effect as we food products and beverages comprising such compositions. The invention also relates to a method for preserving food products and beverages comprising adding the compositions of the invention to the food product or beverage.
Type:
Application
Filed:
November 26, 2012
Publication date:
November 13, 2014
Inventors:
Evangelia Komitopoulou, Ronald H. Skiff, Nathalie Vivien Castioni, Long In Lou
Abstract: The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease.
Type:
Application
Filed:
June 12, 2014
Publication date:
November 6, 2014
Inventors:
William E. Sweeney, Ellis D. Avner, Richard J. Roman